Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 44 publications
Automated detection of active and structural MRI lesions in the sacroiliac joints in axial spondyloarthritis: training and validation across 3 phase III clinical trial datasets.
Journal: Annals of the rheumatic diseases
Published: March 30, 2026
Secukinumab in Moderate-to-Severe Graves Orbitopathy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.
Journal: The Journal of clinical endocrinology and metabolism
Published: October 09, 2025
Automated detection of spinal bone marrow oedema in axial spondyloarthritis: training and validation using two large phase 3 trial datasets.
Journal: Rheumatology (Oxford, England)
Published: March 04, 2025
Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: Results From a Head-to-Head Randomized Phase IIIb Study.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: December 04, 2023
Frequency of CXCR3+ CD8+ T-Lymphocyte Subsets in Peripheral Blood Is Associated With the Risk of Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome Development in Advanced HIV Disease.
Journal: Frontiers in immunology
Published: February 11, 2022
Nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with radiographic axial spondyloarthritis: 4-year results from the MEASURE 2, 3 and 4 phase III trials.
Journal: Rheumatology international
Published: September 27, 2021
Dynamics of T-Lymphocyte Activation Related to Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome in Persons With Advanced HIV.
Journal: Frontiers in immunology
Published: August 12, 2021
A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis.
Journal: Rheumatology and therapy
Published: August 11, 2021
Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT.
Journal: Arthritis research & therapy
Published: June 21, 2021
Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies.
Journal: The Journal of rheumatology
Published: February 26, 2021
Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1.
Journal: BMC musculoskeletal disorders
Published: December 22, 2020
Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies.
Journal: Rheumatology and therapy
Published: October 29, 2020
Last Updated: 09/26/2026